Skip to main content
Sun Pharma Advanced Research Company Ltd. logo

Sun Pharma Advanced Research Company Ltd. — Investor Relations & Filings

Ticker · SPARC ISIN · INE232I01014 LEI · 3358001Y3QHHUNROTJ51 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 638 across all filing types
Latest filing 2026-05-25 Audit Report / Informat…
Country IN India
Listing BSE.NS SPARC

About Sun Pharma Advanced Research Company Ltd.

https://www.sparc.life

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative pharmaceutical products and drug delivery systems. SPARC focuses on creating new chemical entities (NCEs), new biological entities (NBEs), and reformulated products that address significant unmet medical needs. The company utilizes proprietary technology platforms, such as WrapMatrix and Nanotecton, to enhance the efficacy and safety of treatments. Its research pipeline primarily targets therapeutic areas including oncology, neurodegeneration, and ophthalmology. SPARC advances candidates through various stages of clinical trials to provide value-added medicines and novel therapeutic solutions for complex health conditions, leveraging its expertise in formulation and clinical development to improve patient outcomes globally.

Recent filings

Filing Released Lang Actions
Statutory Auditors Certificate in terms of Regulation 169(5) of SEBI ICDRA Regualations, 2018
Audit Report / Information Classification · 85% confidence The document is a certificate from the company’s statutory auditors (S R B C & Co LLP) providing a limited assurance report on receipt of consideration for a preferential allotment of warrants as required under SEBI’s ICDR Regulations. It includes the auditor’s responsibilities, scope, procedures performed, and conclusion. This is a standalone audit report rather than an annual or interim report, earnings release, or regulatory announcement. Therefore, it fits the definition of an Audit Report / Information (Code: AR). FY 2027
2026-05-25 English
Updates
Audit Report / Information Classification · 90% confidence The document is a statutory auditor’s certificate submitted to the stock exchanges under SEBI (ICDR) Regulations. It contains an Independent Auditor’s Report on receipt of consideration for a preferential allotment of warrants, with limited assurance procedures and conclusions. This is a standalone audit report/certificate (not a full annual report), fitting the definition of Audit Report / Information (Code: AR). FY 2027
2026-05-25 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd & PACs
Major Shareholding Notification Classification · 90% confidence The document is a detailed SEBI takeover regulation disclosure under Regulation 29(2), providing shareholding before and after acquisition of convertible warrants, percentages pre- and post-dilution, mode of acquisition, etc. This is a notification by an acquirer of a change in significant share ownership levels crossing regulatory thresholds, not a full report or earnings release. It falls squarely under Major Shareholding Notification.
2026-05-20 English
Newspaper Advertisement for Publication of Financials
Regulatory Filings Classification · 87% confidence The document is a formal stock‐exchange disclosure under Regulation 47 of SEBI LODR, enclosing newspaper advertisements and an extract of audited quarterly/annual financial results. It does not itself contain full financial statements or an Excel supplement, nor is it the management’s full interim report. It simply notifies exchanges of the publication of results in newspapers (with clippings attached). This fits a general regulatory announcement rather than the report itself. Therefore it should be classified as a Regulatory Filing (RNS).
2026-05-20 English
Copy of Newspaper Publication
Earnings Release Classification · 85% confidence The document is a stock‐exchange disclosure under SEBI LODR Regulation 47, enclosing newspaper advertisements that publish the extract of audited financial results (quarterly and annual) for the period ended March 31, 2026. It contains summary financial numbers and is the company’s official initial announcement of its periodic results. This matches the definition of an Earnings Release (ER), i.e., the initial announcement of quarterly/periodical financial results (key highlights only). FY 2026
2026-05-20 English
Update on PDP-716 NDA
Regulatory Filings Classification · 95% confidence The document is an SEBI Listing Regulations (Regulation 30) intimation to stock exchanges regarding a Complete Response Letter from the FDA. It is a regulatory announcement under the Listing Obligations and Disclosure Requirements and does not contain financial statements or earnings data. This fits the catch‐all category for general regulatory announcements, which maps to “Regulatory Filings” (RNS).
2026-05-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.